Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
215647-85-1
Molecular formula
Not available
Molecular weight
~40000 g/mol
Drug class
Pegylated interferon alfarecombinant cytokine immunomodulator and antiviral agent
Mechanism of action
A covalent conjugate of recombinant interferon alfa and polyethylene glycol. Binding to cell-surface interferon receptors triggers JAK-STAT signalling and transcription of interferon-stimulated genes, producing antiviral, antiproliferative and immunomodulatory effects. PEG conjugation reduces clearance and prolongs systemic exposure.
Indications / reported uses
The term peginterferon covers multiple subtype-specific products (for example peginterferon alfa-2a and alfa-2b) with distinct labels. Depending on the subtype and product, indications have included chronic hepatitis B or C and selected myeloproliferative neoplasms; use the exact peginterferon product label for clinical indications.
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Peginterferon Environmental Risk Assessment (ERA) (the Peginterferon ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.